ArticleSexual medicine2026
Clinical characterization and management of persistent genital arousal disorder/genito-pelvic dysesthesia (PGAD/GPD): a registry study.
Article in Sexual medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent genital arousal disorder (PGAD)/genito-pelvic dysesthesia (GPD) is a disabling disease, where patients perceive prolonged genital arousal without sexual desire. The condition mainly occurs in women. Etiopathological considerations reach from peripheral to central nervous system mechanisms. Aim: To clinically and anamnestically characterize patients with PGAD/GPD using data from a dedicated patient registry. Methods: This study comprises a detailed description of 92 patients with PGAD/GPD from a registry data bank. Investigations included clinical characterization of PGAD/GPD-symptoms, assessment of sexual, urogynecological, somatic, and psychiatric history as well as clinical examination and treatments. Outcomes: The primary outcome was to identify common clinical features, symptom patterns, trigger and relieving factors, comorbidities, and therapeutic strategies. Results: Persistent genital arousal disorder symptoms were mostly characterized as tingling and were almost permanently present. In over 80%, PGAD symptoms were located in the clitoris (women) or in the glans penis (men); 50% reported extragenital manifestations. Thirty-four percent described symptoms such as GPD. PGAD presented with high rates of swelling of the genitals (46%), spontaneous orgasms (30%), and extraordinary lubrication (27%). Most frequent trigger factors were mental stress, sitting, wearing tight clothes, and vibration. Relieving factors were mainly distraction, physical exercise, and warmth. Half of the patients stated increased urinary urge. More than 40% stated symptoms of overactive bladder syndrome. About one third reported restless legs symptoms. Almost 70% had comorbid psychiatric diseases, mainly depressive disorders. In most cases, those occurred after the onset of PGAD/GPD symptoms. Further diagnostic procedures covered urogynecological and neurological examinations as well as magnetic resonance imaging of brain, spinal cord, and pelvis. Non-pharmacological therapeutic approaches included among others physiotherapy, psychotherapy, transcutaneous electrical nerve stimulation, neurosurgical procedures, or pudendal block. In the majority, a clear somatic correlate for PGAD/GPD was not found. Clinical Implications: The findings highlight the complex and multifactorial nature of PGAD/GPD, advocating interdisciplinary diagnostics and individualized treatments due to high psychiatric comorbidity and the absence of consistent somatic findings. Strengths and Limitations: The study's strength lies in its large sample size and comprehensive clinical profiling of PGAD/GPD patients; however, its retrospective registry-based design and the absence of a control group represent significant limitations. Conclusion: This first registry-based study of PGAD/GPD in a larger cohort highlights the need for future controlled studies with larger sample sizes and more specified clinical assessments according to consensus statements for a better understanding of the clinical appearance and the etiopathology of PGAD/GPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.